McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4–13

Article  CAS  PubMed  Google Scholar 

Kokudo T, Hasegawa K, Yamamoto S, et al. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. J Hepatol. 2014;61(3):583–588

Article  PubMed  Google Scholar 

Lou J, Li Y, Liang K, et al. Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multi-center analysis. BMC Cancer. 2019;19(1):668

Article  PubMed  PubMed Central  Google Scholar 

le Treut YP, Hardwigsen J, Ananian P, et al. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg. 2006;10(6):855–62

Article  PubMed  Google Scholar 

Wang Y, Yuan L, Ge RL, et al. Survival benefit of surgical treatment for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: results of a retrospective cohort study. Ann Surg Oncol. 2013;20(3):914–922

Article  PubMed  Google Scholar 

Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173

Article  CAS  PubMed  Google Scholar 

Qin S, Kudo M, Meyer T, et al. Tislelizumab vs Sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol. 2023;9(12):1651–1659

Article  PubMed  PubMed Central  Google Scholar 

Huinen ZR, Huijbers EJM, van Beijnum JR, et al. Anti-angiogenic agents—overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol. 2021;18(8):527–540

Article  PubMed  Google Scholar 

Kudo M, Finn RS, Galle PR, et al. IMbrave150: efficacy and safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B unresectable hepatocellular carcinoma: an exploratory analysis of the phase III study. Liver Cancer. 2022;12(3):238–250

Article  PubMed  PubMed Central  Google Scholar 

Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol. 2021;22(7):977–990

Article  CAS  PubMed  Google Scholar 

Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133–1146

Article  CAS  PubMed  Google Scholar 

Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693

Article  PubMed  Google Scholar 

Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Hepatobiliary cancers, Version 2. 2024. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ hcc.pdf

Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition). Liver Cancer. 2018;7(3):235–260

Article  PubMed  PubMed Central  Google Scholar 

Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28(4): 583–705

Hasegawa K, Takemura N, Yamashita T, et al. Clinical Practice Guidelines for Hepatocellular Carcinoma: the Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res. 2023;53(5):383–390

Article  PubMed  Google Scholar 

Li X, Ding X, Liu M, et al. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus. Cancer Med. 2023;12(16):16805–16814

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang Z, Bai T, Wei T, et al. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study. BMC Cancer. 2024;24(1):717

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu XK, Yang LF, Chen YF, et al. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study. EClinicalMedicine. 2023;12(67): 102367

Google Scholar 

Zhang JX, Hua HJ, Cheng Y, et al. Role of transarterial chemoembolization in the era of tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy for unresectable hepatocellular carcinoma: a retrospective propensity score matched analysis. Acad Radiol. 2024;31(4):1304–1311

Article  PubMed  Google Scholar 

McLaughlin M, Patin EC, Pedersen M, et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020;20(4):203–217

Article  CAS  PubMed  Google Scholar 

Sharabi AB, Lim M, DeWeese TL, et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16(13):e498-509

Article  PubMed  Google Scholar 

Li G, Zhao Y, Li K, et al. Effectiveness and safety of the PD-1 inhibitor lenvatinib plus radiotherapy in patients with HCC with main PVTT: real-world data from a tertiary centre. J Hepatocell Carcinoma. 2023;9(10):2037–2048

Article  Google Scholar 

Ning C, Zhang X, Wang Y, et al. Radiation therapy with combination therapy of immune checkpoint inhibitors and antiangiogenic therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2024;118(5):1461–1471

Article  PubMed  Google Scholar 

Chen ZH, Wang K, Zhang XP, et al. A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus. Hepatobiliary Surg Nutr. 2020;9(6):717–728

Article  PubMed  PubMed Central  Google Scholar 

Shi J, Lai EC, Li N, et al. A new classification for hepatocellular carcinoma with portal vein tumor thrombus. J Hepatobiliary Pancreat Sci. 2011;18(1):74–80

Article  PubMed  Google Scholar 

Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72(2):288–306

Article  PubMed  Google Scholar 

Zhu M, Liu Z, Chen S, et al. Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a multicenter, single-arm, phase 2 study. Hepatology. 2024;80(4):807–815

Article  PubMed  Google Scholar 

US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: Nov 27.

Suero M, Botella J, Durán JI. Methods for estimating the sampling variance of the standardized mean difference. Psychol Methods. 2023;28(4):895–904

Article  PubMed  Google Scholar 

Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679

Article  PubMed  PubMed Central  Google Scholar 

Chen ZH, Zhang XP, Wang K, et al. Liver resection versus transcatheter arterial chemoembolization for the treatment of patients with hepatocellular carcinoma and hepatic vein or inferior vena cava tumor thrombus: a propensity score matching analysis. Hepatol Res. 2019;49(4):441–452

Article  PubMed  Google Scholar 

Pao TH, Hsueh WT, Chang WL, et al. Radiotherapy for inferior vena cava tumor thrombus in patients with hepatocellular carcinoma. BMC Cancer. 2019;19(1):560

Article  PubMed  PubMed Central  Google Scholar 

Rim CH, Jeong BK, Kim TH, et al. Effectiveness and feasibility of external beam radiotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium involvement: a multicenter trial in Korea (KROG 17–10). Int J Radiat Biol. 2020;96(6):759–766

Article  CAS  PubMed  Google Scholar 

Lussier DM, Alspach E, Ward JP, et al. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc Natl Acad Sci USA. 2021;118(24):e2102611118

Article  CAS  PubMed  PubMed Central